Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309850 | 0.84 | AXL (0.35) | JAK1JAK3USP1AXLTRPA1 | |
| SCHEMBL24309763 | 0.83 | USP1 (0.33) | JAK1JAK3USP1AXLTRPA1 | |
| SCHEMBL24309759 | 0.82 | HTR1A (0.42) | JAK1JAK3USP1HTR1ADRD2 | |
| SCHEMBL29566738 | 0.82 | HTR1A (0.42) | JAK1JAK3USP1HTR1ADRD2 | |
| SCHEMBL24310657 | 0.81 | AXL (0.31) | JAK1JAK3USP1AXLTRPA1 | |
| SCHEMBL24309546 | 0.80 | PIK3CD (0.34) | MAP4K1 | |
| SCHEMBL24309663 | 0.80 | GPR39 (0.37) | JAK1JAK3AXL | |
| SCHEMBL24310671 | 0.76 | JAK2 (0.36) | JAK1JAK3USP1AXLHTR1A | |
| SCHEMBL24309764 | 0.75 | USP1 (0.32) | JAK1JAK3USP1 | |
| SCHEMBL24309791 | 0.73 | AXL (0.33) | JAK1JAK3USP1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |